OXB highlights launch of Innovation, Technolgoy Excellence Board

OXB highlights the launch of its Innovation and Technology Excellence Board. It will advise OXB on technology priorities, innovation opportunities and emerging trends that support the Company’s growth as a pure-play CDMO. The newly formed advisory board, which held its inaugural meeting last month, will identify opportunities to enhance scientific capabilities to ensure that OXB remains at the forefront of developing innovative technologies. Prof. Dame Kay Davies DPhil FRS, ITEB Committee Chair and Senior Independent Non-Executive Director of OXB, is Emeritus Dr. Lee’s Professor of Anatomy and Co-Director of the MDUK Oxford Neuromuscular Centre at the University of Oxford. Prof. Uwe Buecheler, PhD, previously served as Head of the Biopharma Business Unit at Boehringer Ingelheim.Prof. Bruce Levine, PhD, is the Barbara and Edward Netter Professor in Cancer Gene Therapy and Founding Director of the Clinical Cell and Vaccine Production Facility at the University of Pennsylvania. Prof. Axel Schambach, MD, PhD, is Director of the Institute of Experimental Hematology and Professor for Gene Modification of Somatic Cells at Hannover Medical School. Prof. Luk Vandenberghe, PhD, is the Grousbeck Associate Professor in Gene Therapy at Harvard Medical School and Director of the Grousbeck Gene Therapy Center at Mass Eye and Ear and Mass General Brigham. Dr. Heather Preston, Observer and Independent Non-Executive Director of OXB, is a Senior Advisor to TPG Biotech. The following members of OXB’s senior leadership team also sit on the Innovation and Technology Excellence Board: Dr. Frank Mathias, CEO, Thierry Cournez, COO, Kyriacos Mitrophanous, CIO and,Sebastien Ribault, CBO.